- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.03. | Aspire Biopharma and Microsize collaborate for alprazolam powder formulation | ||
| 04.03. | Esperion to acquire Corstasis for cardiovascular franchise expansion | ||
| 03.03. | OSE narrows pipeline focus amid Boehringer MASH collaboration retreat | ||
| 03.03. | Pharma rings the changes as CEO shake-up continues | ||
| 03.03. | Rallybio to acquire Candid Therapeutics | ||
| 03.03. | Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production | ||
| 03.03. | Kairos Pharma signs deal for Celyn Therapeutics' CL-273 | ||
| 02.03. | Moderna's dual Covid-flu vaccine poised for EMA approval on positive CHMP take | ||
| 02.03. | Sanofi receives CHMP recommendation for Dupixent expansion in Europe | ||
| 02.03. | FDA approves Ascendis Pharma's weekly Yuviwel for paediatric dwarfism | ||
| 02.03. | Sanofi receives CHMP recommendation for Dupixent approval in Europe | ||
| 02.03. | BioMarin receives FDA approval for Palynziq use in adolescents | ||
| 27.02. | Boehringer inks $500m Sitryx deal, secures CPNV-driven Hernexeos approval | ||
| 27.02. | Generate Biomedicines secures $400m IPO in flurry of February listings | ||
| 27.02. | Asahi Kasei to acquire Aicuris Anti-infective Cures for $920.7m | ||
| 27.02. | Quotient and Ipsen extend partnership for ultra-rare disease therapy | ||
| 26.02. | MHRA and police seize 2,000 illegal weight loss drugs after raiding criminal facility | ||
| 26.02. | IQVIA to acquire Charles River drug discovery assets | ||
| 26.02. | Novo Nordisk and Vivtex collaborate for oral medicines development | ||
| 25.02. | GSK continues dealmaking spree with $950m 35Pharma acquisition | ||
| 25.02. | RFK Jr faces legal challenge from 15 US states over childhood vaccine recommendations | ||
| 25.02. | Slate Medicines raises $130m in funds to progress anti-PACAP treatments | ||
| 25.02. | NorthX Biologics and Demeetra collaborate on GMP manufacturing and CLD | ||
| 24.02. | Gene editing takes centre stage in FDA's new rare disease approval pathway | ||
| 24.02. | GSK backs siRNA modality through $1bn Frontier deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.